Table 2.
Univariate analysis of factors associated with survival and progression in HGG patients
| Variable | HGG | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| OS | PFS | |||||
|
|
|
|||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (≥60 vs. <60 y) | 1.528 | 1.032-2.264 | 0.034 | 1.607 | 1.084-2.382 | 0.018 |
| VSIG4 (High vs. Low) | 1.670 | 1.066-2.619 | 0.025 | 1.530 | 0.994-2.354 | 0.053 |
| Gender (Female vs. male) | 0.814 | 0.570-1.163 | 0.258 | 0.759 | 0.533-1.081 | 0.126 |
| Primary (vs. secondary) | 0.686 | 0.426-1.104 | 0.120 | 0.734 | 0.462-1.168 | 0.192 |
| Seizure (Yes vs. no) | 0.847 | 0.521-1.377 | 0.503 | 0.974 | 0.611-1.550 | 0.910 |
| IICP (Yes vs. no) | 0.953 | 0.682-1.333 | 0.780 | 0.892 | 0.640-1.243 | 0.499 |
| Cystic Degeneration (Yes vs. no) | 0.750 | 0.510-1.102 | 0.142 | 0.818 | 0.561-1.190 | 0.293 |
| Necrosis on MRI (Yes vs. no) | 0.950 | 0.614-1.469 | 0.817 | 1.178 | 0.774-1.794 | 0.445 |
| MTD (≥5 vs <5 cm) | 1.047 | 0.745-1.472 | 0.792 | 1.209 | 0.864-1.692 | 0.268 |
| Resection Degree | 0.009 | 0.037 | ||||
| Subtotal vs. total | 1.224 | 0.816-1.836 | 0.329 | 1.223 | 0.824-1.815 | 0.318 |
| Partial vs. total | 4.312 | 1.557-11.943 | 0.005 | 3.453 | 1.253-9.516 | 0.017 |
| Biopsy vs. total | 3.222 | 1.012-10.262 | 0.048 | 2.637 | 0.803-8.385 | 0.100 |
| Chemotherapy (Yes vs. no) | 0.783 | 0.542-1.132 | 0.194 | 0.887 | 0.615-1.281 | 0.524 |
| Radiotherapy (Yes vs. no) | 0.644 | 0.450-0.921 | 0.016 | 0.708 | 0.496-1.009 | 0.056 |
| WHO Grade | ||||||
| IV vs. III | 3.051 | 1.973-4.717 | <0.001 | 2.794 | 1.837-4.250 | <0.001 |
| Lineage (Oligodendroglial vs. astrocytic) | 0.211 | 0.078-0.574 | 0.002 | 0.259 | 0.106-0.636 | 0.003 |
Note: Univariate analysis, Cox proportional hazards regression model. Abbreviations: IICP, increased intracranial pressure; MTD, mean tumor diameter; NA, not applicable; HR, Hazard ratio; OS, overall survival; PFS, progression-free survival.